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the reduction in the annual probability of local recurrence with the addition of an EBB; the reduction in the annual probability of death with the addition of an EBB; the probability of salvaging local recurrence by mastectomy and reconstructive surgery, following treatment with or without an EBB; the annual probability of death after the first diagnosis of distant metastases; the annual probability of death after the progression of metastases following first remission; and the annual probability of death from causes other than breast cancer.
The following health state utilities were also assessed: treatment with or without an EBB, without evidence of recurrence; treatment with or without an EBB, with local recurrences salvaged by mastectomy and reconstructive surgery; a diagnosis of distant metastases and undergoing salvage chemotherapy; in remission with distant metastases.
Study designs and other criteria for inclusion in the review
The inclusion criteria for the studies were unclear. The efficacy data from two randomised clinical trials were used in preference to reports of retrospective series.
Sources searched to identify primary studies
The authors did not report the search strategy used, or the sources searched to identify the primary studies.
Criteria used to ensure the validity of primary studies
The criteria used to ensure the validity of the primary studies were unclear.
Methods used to judge relevance and validity, and for extracting data
The methods used to judge the relevance and validity of the studies, and to extract the data, were not specified.
Number of primary studies included
The effectiveness data were derived from two studies.
Methods of combining primary studies
The primary data sources were not combined.
Investigation of differences between primary studies
The authors did not investigate or explain explicitly the differences between the primary data sources in terms of the number of participants, interventions and outcome measures. The decision to estimate the baseline from the B-06 trial data (see Other Publications of Related Interest no.1), rather than from the Lyon trial (see Other Publications of Related Interest no.2), was based on the differences in the follow-up period and the clinical practice of the two trials.
Results of the review
The base-case estimates for the outcomes included in the model were: 0.92% for the annual probability of local recurrence with tangential whole-breast radiation therapy alone; 20% for the reduction in the annual probability of local recurrence with the addition of an EBB; 0% for the reduction in the annual probability of death with the addition of an EBB; 100% for the probability of salvaging local recurrence by mastectomy and reconstructive surgery, following treatment with or without an EBB; 50% for the annual probability of death after the first diagnosis of distant metastases; 100% for the annual probability of death following progression of the metastases after the first remission; and 0.8 to 2% for the annual probability of death due to causes other than breast cancer.
Measure of benefits used in the economic analysis
The model estimated the costs and QALYs associated with each treatment strategy during each yearly cycle. The authors stated that the quality of life data were incorporated into the analysis through the use of utilities, which were measured using the standard gamble technique. The health state utilities were derived from a single published study using standard gamble on 97 patients, and from expert opinion. The utility values were: 0.92 for treatment with or without an EBB, without evidence of recurrence; 0.82 for treatment with or without an EBB, with local recurrences salvaged by mastectomy and reconstructive surgery; 0.72 for a diagnosis of distant metastases and undergoing salvage chemotherapy; and 0.75 for in remission with distant metastases.
Direct costs
The direct medical costs of the facility, professional staff, time and travel were considered in the analysis. The costs of the facility and professional staff were derived from published data. The facility costs were estimated by multiplying the Medicare charges for the treatment of planning, dosimetry and administration of eight EBB treatments, by the Medicare cost-to-charge ratio for radiation therapy at the Medical College of Virginia in 1995. The professional costs were estimated by multiplying the relative units of work associated with administering the boost, as estimated by Healthcare Consultants Inc., by an estimate of the cost per unit of work ($8.00) on the basis of the California and Florida state medical associations' physician payment scales.
The time costs were calculated by multiplying the time spent by the patient in travelling to and undergoing eight additional treatments, by an estimate of the average hourly wage for women in their 60s ($9.40 per hour). The transportation costs were estimated by multiplying estimates of the miles travelled to undergo each additional treatment by the cost per mile ($0.31), then adding the cost of parking ($2.00). The future costs and benefits were all discounted at a rate of 3% in the baseline model.
Statistical analysis of costs
No statistical analysis of costs was carried out.
Indirect Costs
No indirect costs were included in the analysis.
